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Abstract 
According with the new European and American guidelines, 
the role of an electrophysiology study (EPS) remains small for 
risk stratification for sudden cardiac death (SCD), limited to 
patients with an LVEF >35%, mostly indicated when evaluating 
symptoms suggestive of ventricular tachyarrhythmias, including 
palpitations, presyncope and syncope, mainly in those with 
underlying structural heart disease, particularly coronary artery 
disease in the setting of a remote myocardial infarction rather 
than non-ischemic cardiomyopathy. Importantly, there is no 
indication or need of EPS as a prerequisite for any of the standard 
indications of implantable cardioverter defibrillator (ICD) for 
secondary or primary prevention of SCD. Rhythmos 2018;13(1): 
1-5.   
Key Words: sudden cardiac death; electrophysiology study; 
programmed ventricular stimulation; implantable cardioverter 
defibrillator; cardiac resynchronization therapy  
Abbreviations: ARVC = arrhythmogenic right ventricular 
cardiomyopathy; CAD = coronary artery disease; CMR = cardiac 
magnetic resonance imaging; CRT = cardiac resynchronization therapy; 
EPS = electrophysiology study; ICD = implantable cardioverter 
defibrillator; LOE = level of evidence; LV = left ventric-le(-ular); LVEF 
= left ventricular ejection fraction; MI = myocardial infarction; NICM 
= non-ischemic cardiomyopathy; NYHA = New York Heart 
Association; RCTs = randomized controlled studies; RVOT = right 
ventricular outflow tract; SCD = sudden cardiac death; SVT = 
supraventricular tachycardia; VA = ventricular arrhythmia; VF = 
ventricular fibrillation; VT = ventricular tachycardia   
Role of EPS for risk stratification 
With the completion of randomized controlled trials 
(RCTs) 1-4 for primary and secondary prevention of sudden 
cardiac death (SCD) documenting the superiority of 
implantable cardioverter defibrillator (ICD) over 
antiarrhythmic drugs with selection of patients based 
primarily on the type of clinical arrhythmia, the underlying 
heart disease and the left ventricular (LV) ejection fraction 
(LVEF) and secondarily on New York Heart Association 
(NYHA) classification of symptoms, the role of an 
electrophysiology study (EPS) has markedly been 
downgraded. 5, 6 Thus, the guidelines solely for the 
performance of EPS have not been updated since 1995.7 In 
the cases of secondary prevention of SCD, there is no need 
for electro-pharmacological testing any more,8, 9 while in 
the instances of primary prevention, the positive predictive 
value of EPS, similar to that of a bunch of other tests (e.g. 
signal-averaged ECG, heart rate variability, T-wave 
alternans, etc.) has remained low and thus their value has 
been questioned.10-15 Furthermore, the negative predictive 
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value of EPS is even lower, while the invasive nature of 
this test limits its acceptance as a risk stratifier.16 For 
secondary prevention, there is no cut-off value for the 
LVEF, however, for primary prevention an LVEF <35% 
has been adopted by the guidelines as an indication of ICD 
implantation. A similar cut-off (LVEF<35%) has been set 
for implantation of a cardiac resynchronization therapy 
(CRT) defibrillator (CRT-D) device together with the 
width (>120-150 ms) of the QRS complex. LVEF has 
remained as the best available predictor despite its several 
limitations in terms of sensitivity and specificity in the 
absence of a better risk stratifier, either as a single marker 
or in the form of a risk score. Thus, for all the above 
instances, there is no need to perform an EPS. However, 
for greater values (>35%) of LVEF, there is a resurgence 
of interest in the performance of an EPS for risk 
stratification in patients with ischemic and non-ischemic 
cardiomyopathy (NICM)17, 18 in an attempt to identify 
more patients at risk for SCD, as it has been poignantly 
realized for a long time now that many patients with LVEF 
>35% are also susceptible to the occurrence of SCD.19 EPS 
as an old and classical tool of risk stratification combined 
with newer tools, such as cardiac magnetic resonance 
imaging (CMR), may offer some hope in expanding the 
spectrum of risk stratification and SCD protection for more 
patient categories.  
When performing an EPS, only the induction of 
sustained monomorphic ventricular tachycardia (VT) is 
considered a specific finding, while the induction of 
polymorphic VT or ventricular fibrillation (VF) are 
nonspecific findings,15, 20 except perhaps for the induction 
of VF with <2 ventricular extrastimuli in patients with 
Brugada syndrome.21 Some may consider that the 
reproducible induction of polymorphic VT/VF with a low 
(<2) number of extrastimuli may be of some clinical 
significance.15 In general, induction of polymorphic 
ventricular arrhythmias (VA) with programmed 
ventricular stimulation applied at the right ventricular 
outflow tract (RVOT), particularly with use of 3 
ventricular extrastimuli, are always nonspecific findings 
under any circumstances.  The sensitivity and specificity 
of EPS is always higher in patients with coronary artery 
disease (CAD) compared with patients with NICM. 
Finally, although a positive EPS with inducible 
monomorphic VT may predict the occurrence of clinical 
monomorphic VT, its ability to predict polymorphic VT or 
VF is limited.   
Indications for EPS 
American Guidelines. According with the new 
(2017) ACC/AHA/HRS guidelines,22 performing an EPS 
is recommended in the following instances:  
1. In patients with ischemic cardiomyopathy, NICM, or 
adult congenital heart disease who have syncope or other 
VA symptoms and who do not meet indications for a 
primary prevention ICD, an EPS can be useful for 
assessing the risk of sustained VT (Class IIa / LOE B-R)  
2. In patients who meet criteria for ICD implantation, an 
EPS for the sole reason of inducing VA is not indicated 
for risk stratification (Class III / LOE B-R)  
3. An EPS is not recommended for risk stratification for 
VA in the setting of long QT syndrome (LQTS), 
catecholaminergic polymorphic ventricular tachycardia 
(CPVT), short QT syndrome (SQTS), or early 
repolarization syndromes (Class III / LOE B-NR)   
In the text accompanying the Guidelines it is made 
clear that in the current era of ICD therapy and its proven 
benefit in the primary and secondary prevention of SCD, 
the role of EPS is diminished:  
● Patients with heart failure and LVEF ≤35% generally 
will have an indication for an ICD and specific induction 
of VT/VF before implantation is not necessary.  
● Patients with LVEF >35% and unexplained syncope or 
near-syncope may benefit from an EPS to determine if 
VT/VF is the cause of symptoms and to guide further 
therapy.  
● Induction of VT/VF is often attempted before catheter 
ablation of the arrhythmia substrate to guide the procedure 
and to determine the success of the intervention after 
ablation is performed.  
● An EPS can be used to determine the mechanism of a 
wide complex tachycardia.  
It is further emphasized that in patients who meet 
criteria for ICD implantation (i.e., heart failure and LVEF 
<35%), data do not support the routine use of EPS solely 
for risk stratification, as such patients have been shown to 
derive survival benefit from the ICD.  
An EPS may be helpful, however, in selected patients 
suspected to have preexcitation or supraventricular 
arrhythmias as the cause of symptoms or wide complex 
tachycardias that warrant definitive diagnosis and 
management. Supraventricular tachycardia (SVT) leading 
to VT/VF or aberrantly conducted SVT may also be 
suspected in younger patients or those with a preserved 
LVEF. Induction of SVT and ablation may then be 
curative, with no need for an ICD. In such cases, failure to 
induce VT/VF after elimination of the substrate for SVT 
would be expected.  
Finally, it is pointed out that risk stratification for 
channelopathies is generally made on the basis of 
symptoms, the ECG, exercise treadmill testing, and the 
results of genetic testing. The EPS (i.e., programmed 
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ventricular stimulation) does not have prognostic value for 
risk stratification in these patients.  
European Guidelines. However, one may argue that 
European countries should abide by the ESC guidelines. 
According to these guidelines, last updated in 2015,23 an 
EPS is recommended as follows: 
1) In patients with CAD for diagnostic evaluation of 
patients with remote myocardial infarction (MI) with 
symptoms suggestive of VAs, including palpitations, 
presyncope and syncope (class I, LOE B).  
2) In patients with syncope when bradyarrhythmias or 
tachyarrhythmias are suspected, based on symptoms (e.g. 
palpitations) or the results of non-invasive assessment, 
especially in patients with structural heart disease (class 
I, LOE C) 
3) EPS may be considered for the differential diagnosis 
of arrhythmogenic right ventricular cardiomyopathy 
(ARVC) and benign RVOT tachycardia or sarcoidosis 
(class IIb, LOE B) 
In particular, for patients with unexplained syncope, 
the indication for EPS is phrased as follows: 
“Programmed ventricular stimulation (PVS) should be 
considered in survivors of an MI with preserved LV 
function and otherwise unexplained syncope (class IIa, 
LOE C).” 
In the text, the guidelines emphasize that in patients 
with cardiomyopathies and inherited primary arrhythmia 
syndromes, EPS might play a role in ARVC or NICM 
patients, while it does not contribute to identifying high-
risk patients in hypertrophic cardiomyopathy (HCM) 
(class III). Among the channelopathies, EPS is not 
indicated in LQTS, CPVT and SQTS, while its utility is 
debated in Brugada syndrome. With regards to the latter 
group, the article that accompanies the American 
guidelines24  reviews the evidence from 6 studies of 1138 
asymptomatic patients with Brugada syndrome about the 
value of EPS. Inducible VA on EPS was identified in 390 
(34.3%) patients. Primary analysis limited to 5 of the 6 
studies found an odds ratio of 2.3 (p=0.2) for major 
arrhythmic events (sustained VAs, SCD, or appropriate 
ICD therapy) in asymptomatic patients with Brugada 
syndrome and inducible VA on EPS versus those without 
inducible VA. 
In patients with syncope, it is noted that EPS is useful 
in patients with LV dysfunction due to a previous MI 
(LVEF <40%) but is not sensitive in patients with NICM. 
Induction of polymorphic VT or VF, especially with 
aggressive stimulation techniques, is not specific. In 
CAD, the diagnostic yield may reach 50%.   
Table 1. Current Indications for an Electrophysiology 
Study (EPS) for Sudden Cardiac Death (SCD) Risk 
Stratification  
● patients with underlying structural heart disease and 
an LVEF >35% or who do not meet indications for a 
primary prevention ICD, when evaluating symptoms 
suggestive of ventricular tachyarrhythmias, including 
palpitations, presyncope and syncope   
● before catheter ablation of the arrhythmia substrate to 
guide the procedure and to determine the success of the 
intervention after ablation is performed  
● to determine the mechanism of a wide complex 
tachycardia   
● ? may be considered for the differential diagnosis of 
ARVC and benign RVOT tachycardia  
● ? asymptomatic patients with Brugada syndrome 
_____________________________________________ 
ARVC = arrhythmogenic right ventricular cardiomyopathy; ICD 
= implantable cardioverter defibrillator; LVEF = left ventricular 
ejection fraction; RVOT = right ventricular outflow tract    
ICD for secondary Prevention of SCD  
It is clear from the guidelines that EPS is not indicated 
and not needed when a patient suffers from documented 
VT/VF (in the absence of reversible causes or within 48 h 
after MI) wherein an ICD is recommended for secondary 
prevention of SCD.   
ICD for primary prevention of SCD  
According to both American and European guidelines, 
an ICD is indicated for primary prevention of SCD in the 
following instances, without the need for an EPS:   
1) ICD therapy is recommended to reduce SCD in patients 
with symptomatic heart failure (NYHA class II–III) and 
LVEF ≤35% after ≥3 months of optimal medical therapy 
who are expected to survive for at least 1 year with good 
functional status: class I/LOE A for ischemic etiology (at 
least 6 weeks after MI), class I / LOE B for non-ischemic 
etiology.  
The European guidelines state that currently there are 
no RCTs demonstrating the value of an ICD in 
asymptomatic patients (NYHA class I) with systolic 
dysfunction (LVEF ≤35–40%) or in patients with heart 
failure and preserved LVEF >40–45%, thus ICDs are not 
recommended for primary prevention in these patients.  
However, the American guidelines provide the 
following criteria for ICD implantation in patients with 
NYHA class I and LV dysfunction, based on the two 
MADIT trials:2, 3, 22 an ICD is recommended in patients 
with ischemic heart disease and LVEF of <30% who are at 
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least 40 days’ post-MI and at least 90 days post-
revascularization (class I / LOE A); while in patients with 
NICM, an ICD is recommended when LVEF is <35% 
(class IIb, LOE B-R), based on the DEFINITE trial.25 The 
criteria differ for patients with NICM due to a Lamin A/C 
mutation, whereby an ICD is recommended if they have 
>2 risk factors (non-sustained VT, LVEF <45%, non-
missense mutation, and male sex) (class IIa/ LOE B-NR).  
Importantly, no EPS is recommended as a prerequisite 
for any of the above indications of ICD for primary 
prevention. The only group that the American guidelines 
indicate the usefulness of an EPS to determine the need for 
an ICD includes patients fitting the group of the MUSTT 
trial,26 i.e. patients with non-sustained VT due to prior MI, 
LVEF of <40% and inducible sustained VT or VF at EPS 
(class I / LOE B-R).  Practically, based on all the above 
indications, EPS may be of use for ischemic patients with 
35%<LVEF<40%.   
Conclusion  
Despite a resurgence in the interest for performing an 
EPS for risk stratification of cardiac patients for SCD, 
according to the new European and American guidelines, 
the role of EPS remains small, limited to patients with an 
LVEF >35%, particularly indicated when evaluating 
symptoms suggestive of ventricular tachyarrhythmias, 
including palpitations, presyncope and syncope mainly in 
those with underlying CAD (remote MI) rather than 
NICM. Importantly, there is no indication or need for EPS 
as a prerequisite for any of the standard indications of ICD 
implantation either for primary or secondary prevention of 
SCD. EPS is not recommended for risk stratification of 
patients with primary electrical disease (channelopathies), 
except perhaps for asymptomatic patients with Brugada 
syndrome, nor for patients with hypertrophic 
cardiomyopathy. Rarely, may EPS be useful in the 
differential diagnosis of ARVC and benign RVOT 
tachycardia. Finally and plausibly, the invasive nature of 
EPS is a major obstacle for its wider acceptance as a risk 
stratifier.   
Perspective  
The development of optimal risk-stratification tools 
that can identify patients specifically at risk for SCD who 
could maximally benefit from ICD implantation remains a 
vexing challenge. Unfortunately, most of the broadly 
adopted and widely used risk stratification tools and scores 
are not specific for SCD. Decreased LVEF is a prime 
example of a problematic risk stratifier that has no ability 
to explicitly predict SCD; it mainly identifies patients at 
overall high cardiac mortality risk. However, even the 
more sophisticated tools, like heart rate variability, T-wave 
alternans, signal-averaged ECG, etc., are also only useful 
at sorting out high mortality risk patients, without 
specifically predicting arrhythmic risk, while all of them 
are suffering from low predictive values. Combining these 
tests may increase the predictive value but the number of 
patients having some or all of them positive sharply 
diminishes.  
Among all of these imperfect tools, EPS appears to be 
the only well-established risk stratification tool 
specifically for SCD, but this test also suffers from 
relatively low predictive values, while its major drawback 
is its invasive nature. Thus, better noninvasive tools are 
urgently needed. In this direction contrast-enhanced CMR 
detecting myocardial fibrosis and scar with late 
gadolinium enhancement (LGE) appears to be a powerful 
risk stratifier for patients with NICM.17, 18 This apparently 
relates to the fact that myocardial scar promotes VAs via 
mechanisms of heterogenous myocardial conduction and 
electrical reentry that may lead to SCD. Importantly, this 
non-invasive risk stratifier seems to be also useful in 
patients with LVEF >35%, where there is greater and more 
dire need for SCD risk stratification, as there are currently 
no guidelines applied and no means to predict and prevent 
SCD in this patient population. The ongoing randomized 
CMR_Guide trial (https://clinicaltrials.gov/ct2/show/ 
NCT01918215) will test whether a routine CMR-guided 
management strategy of ICD insertion (in LGE-positive 
patients) is superior to a conservative strategy of standard 
care among patients with mild-moderate LV systolic 
dysfunction (LVEF 36%–50%).   
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